We are live on ! Find out more

Ocular Therapeutix

OCUL

Market cap $2.35B

10.72 USD

+0.23

2.19%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

11.00

+0.28

2.61%

1 day

2.19%

5 days

1.52%

1 month

6.77%

3 months

19.24%

6 months

24.22%

Year to date

-9.31%

1 year

-14.51%

5 years

0.19%

10 years

64.67%

About: Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Employees: 325

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 18.8%

Neutral 81.3%

Negative 0%

Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences

BEDFORD, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in September and October 2026.

Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences

Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript

Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript

Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript

Why Is Ocular Therapeutix Stock Gaining Monday?

Ocular Therapeutix Inc. (NASDAQ:OCUL) stock is trading higher on Monday as the stock reacts to underwhelming data from its rival, EyePoint Inc. (NASDAQ:EYPT).

Why Is Ocular Therapeutix Stock Gaining Monday?

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Beth Rada, the Company's new SVP, Government Affairs and Public Policy. The awards were made as an inducement material to the recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to eight newly hired non-executive employees.

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix: AXPAXLI Can Turn Retina Capacity Into A Commercial Moat

Ocular Therapeutix (OCUL) is positioned for a potential 2027 launch of AXPAXLI, with a de-risked regulatory path and strong Phase 3 efficacy data. AXPAXLI's annual dosing and clinic productivity benefits could drive adoption beyond wet AMD, targeting broader retinal indications including diabetic retinopathy. The FDA has agreed to an NDA submission in Q4 2026 based on SOL-1 data and interim safety from SOL-R, reducing near-term regulatory risk.

Ocular Therapeutix: AXPAXLI Can Turn Retina Capacity Into A Commercial Moat

Zacks Investment Research

Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.39 per share a year ago.

Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Ocular's AXPAXLI TM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment

Ocular Therapeutix NASDAQ: OCUL said it remains on track to submit a New Drug Application for AXPAXLI in wet age-related macular degeneration in the fourth quarter, after what Executive Chairman, President and CEO Dr. Pravin Dugel described as alignment with the U.S. Food and Drug Administration on the planned filing package.

Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to eleven newly hired non-executive employees.

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

See News Rankings

Price charts implemented using Lightweight Charts™